We utilized the γ-secretase inhibitor, nirogacestat, recently FDA approved to treat desmoid tumors.12 We report average IC50 values of nirogacestat and the MEK inhibitor, mirdametinib, across various MPNST patient samples (Table 1 and Supplementary Figure S4A). Here, MAP2K7 is linked to desmoid tumor.